Baijin Life Science Holdings Limited submitted its Monthly Return for Equity Issuer for the period ended 31 July 2026, outlining the following key points:

1. Share Capital Structure • Authorised capital remained steady at 10.00 billion ordinary shares with a par value of HKD 0.02 each, equivalent to HKD 200.00 million. • Issued share capital was unchanged at 932.25 million shares. The company held no treasury shares during the month.

2. Public Float Baijin Life Science confirmed compliance with the Main Board’s minimum 25% public-float requirement as at 31 July 2026.

3. Share Option Activity • Under the Share Option Scheme adopted on 30 September 2024, 67.93 million new share options were granted during July. • Outstanding options at month-end totalled 67.93 million, with no options exercised and no funds raised in the period. • No new shares were issued, nor were any treasury shares transferred, relating to these options in July.

4. Absence of Other Equity Movements The issuer reported no activity in warrants, convertible securities, other share issuance arrangements, share repurchases, or treasury-share movements for the month.

All disclosures were confirmed by Director Cheung Sze Ming and filed with Hong Kong Exchanges and Clearing Limited on 3 August 2026.